Skip to main content
. 2021 Aug 26;12:5138. doi: 10.1038/s41467-021-25391-z

Fig. 4. Effects of IMOD combining PDT and daily administration of ICB antibodies on tumor growth and survival in mice.

Fig. 4

a, b Treatments performed in subcutaneous (s.c.) E0771 tumors in C57BL/6 mice (n = 6–14). Treatment regimens in (a), (c), (d), and (e): 1#, untreated; 2#, IMOD/PDT (q3d × 2); 3#, ICB (i.p. q3d × 4); 4#, ICB (i.t. q3d × 4); 5#, ICB (i.p. daily); 6#, IMOD/PDT (q3d × 2) + ICB (i.p. q3d × 4); 7#, IMOD/PDT × 2/ICB (daily). Abbreviation: i.p., intraperitoneal; i.t., intratumoral; q3d × 4, every three days for four times. IMOD/PDT × 2/ICB (daily): treatment with PDT (q3d × 2) and ICB antibodies (daily) via IMOD. For additional treatment groups, see Supplementary Fig. 4e. c Treatments performed in s.c. 4T1 tumors in BALB/c mice (n = 7–11). d Treatments performed in s.c. B16F10 tumors in C57BL/6 mice (n = 7–12). e Treatments performed in MMTV-PyMT transgenic female mice with spontaneous breast tumors (n = 4–7). In (a), (c), (d), and (e), statistical significance was determined using log-rank tests. * P < 0.05, ** P < 0.01, *** P < 0.001. Source data and P values in a, c, d, e are provided in the Source data file.